Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

EMORY UNIVERSITY

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1836-12-10

Employees: 10K

Market Cap: -

Website: http://www.emory.edu

Clinical Trials

Dexcom Continuous Glucose Monitoring in Long-term Care

Not Applicable

Completed

Conditions: Diabetes Mellitus, Type 2
Diabetes

Interventions: Diagnostic Test: POC Blood Glucose Test + Blinded CGM
Device: Dexcom G6 CGM with GTS

First Posted Date: 2021-03-26

Last Posted Date: 2023-11-13

Lead Sponsor: Emory University

Target Recruit Count: 100

Registration Number: NCT04818242

Locations: 🇺🇸
A.G. Rhodes, Atlanta, Georgia, United States
🇺🇸
Emory Wesley Woods Hospital, Atlanta, Georgia, United States

Cost and Shared Decision-Making for Heart Failure

Not Applicable

Completed

Conditions: Chronic Heart Failure

Interventions: Behavioral: Medication Cost Information
Behavioral: Heart Failure Medicines Checklist

First Posted Date: 2021-03-11

Last Posted Date: 2023-12-15

Lead Sponsor: Emory University

Target Recruit Count: 247

Registration Number: NCT04793880

Locations: 🇺🇸
UCHealth Heart and Vascular Center Clinics, Aurora, Colorado, United States
🇺🇸
Emory University Hospital Midtown, Atlanta, Georgia, United States
🇺🇸
Emory Clinic, Emory University Hospital, Atlanta, Georgia, United States

and more 1 locations

Fiber-rich Foods to Treat Obesity and Prevent Colon Cancer

Not Applicable

Active, not recruiting

Conditions: Colon Cancer
Obesity

Interventions: Dietary Supplement: Healthy American Diet
Dietary Supplement: High Fiber Diet Featuring Legumes (HLD)

First Posted Date: 2021-03-03

Last Posted Date: 2025-02-05

Lead Sponsor: Emory University

Target Recruit Count: 60

Registration Number: NCT04780477

Locations: 🇺🇸
Rollins School of Public Health, Emory University, Atlanta, Georgia, United States

Iberdomide Alone or in Combination With Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma

Phase 2

Recruiting

Conditions: Smoldering Plasma Cell Myeloma

Interventions: Drug: Dexamethasone
Drug: Iberdomide Hydrochloride
Other: Quality-of-Life Assessment

First Posted Date: 2021-03-01

Last Posted Date: 2024-07-15

Lead Sponsor: Emory University

Target Recruit Count: 68

Registration Number: NCT04776395

Locations: 🇺🇸
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States

PROUD Study - Preventing Opioid Use Disorders

Phase 4

Terminated

Conditions: Opioid Use
Anesthesia

Interventions: Behavioral: Guided mindfulness exercises
Other: Self-administered aromatherapy
Drug: Baby aspirin
Drug: Tylenol/Acetaminophen
Drug: Pregabalin
Drug: Prednisone
Drug: Meloxicam
Drug: Prilosec
Drug: Tramadol
Drug: Voltaren
Drug: Zofran
Drug: Pepcid
Drug: Reglan
Drug: Versed
Drug: Lidocaine
Drug: Propofol
Drug: Ancef
Drug: Tranexamic Acid (TXA)
Drug: Decadron
Drug: Bupivacaine hydrochloride
Drug: Toradol

First Posted Date: 2021-02-23

Last Posted Date: 2023-06-22

Lead Sponsor: Emory University

Target Recruit Count: 57

Registration Number: NCT04766996

Locations: 🇺🇸
Emory University Orthopaedic and Spine Hospital, Atlanta, Georgia, United States

MRX-2843 and Osimertinib for the Treatment of Advanced EGFR Mutant Non-small Cell Lung Cancer

Phase 1

Recruiting

Conditions: Advanced Lung Non-Small Cell Carcinoma
Stage IV Lung Cancer AJCC v8
Stage IVA Lung Cancer AJCC v8
Metastatic Lung Non-Small Cell Carcinoma
Stage IVB Lung Cancer AJCC v8

Interventions: Drug: Flt3/MerTK Inhibitor MRX-2843
Drug: Osimertinib

First Posted Date: 2021-02-21

Last Posted Date: 2025-05-09

Lead Sponsor: Emory University

Target Recruit Count: 69

Registration Number: NCT04762199

Locations: 🇺🇸
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States

The Precision CAD Trial

Not Applicable

Recruiting

Conditions: Coronary Artery Disease

Interventions: Other: Registry
Other: Medical/Behavioral therapy
Other: Standard of Care

First Posted Date: 2021-02-16

Last Posted Date: 2024-11-08

Lead Sponsor: Emory University

Target Recruit Count: 450

Registration Number: NCT04755413

Locations: 🇺🇸
Emory Johns Creek Hospiatl, Atlanta, Georgia, United States
🇺🇸
Emory University Hospital Midtown, Atlanta, Georgia, United States
🇺🇸
Emory University Hospital, Atlanta, Georgia, United States

and more 2 locations

Isatuximab As Upfront Therapy for the Treatment of High Risk AL Amyloidosis

Phase 1

Active, not recruiting

Conditions: AL Amyloidosis

Interventions: Drug: Bortezomib
Drug: Cyclophosphamide
Drug: Dexamethasone
Biological: Isatuximab

First Posted Date: 2021-02-15

Last Posted Date: 2025-02-03

Lead Sponsor: Emory University

Target Recruit Count: 11

Registration Number: NCT04754945

Locations: 🇺🇸
University of California, Orange, California, United States
🇺🇸
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸
Emory University Hospital Midtown, Atlanta, Georgia, United States

and more 3 locations

Fluciclovine and PSMA PET/CT for the Classification and Improved Staging of Invasive Lobular Breast Cancer

Phase 1

Completed

Conditions: Anatomic Stage IV Breast Cancer AJCC v8
Metastatic Breast Lobular Carcinoma
Invasive Breast Lobular Carcinoma
Prognostic Stage IV Breast Cancer AJCC v8

Interventions: Procedure: Computed Tomography
Drug: Fluciclovine F18
Drug: Gallium Ga 68 Gozetotide
Procedure: Positron Emission Tomography

First Posted Date: 2021-02-11

Last Posted Date: 2025-01-17

Lead Sponsor: Emory University

Target Recruit Count: 20

Registration Number: NCT04750473

Locations: 🇺🇸
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States

Perioperative Testosterone Replacement Therapy for the Improvement of Post-Operative Outcomes in Patients With Low Testosterone

Phase 1

Recruiting

Conditions: Malignant Urinary System Neoplasm
Hypogonadism
Urinary System Disorder
Urinary System Neoplasm

Interventions: Other: Best Practice
Procedure: Quality-of-Life Assessment
Drug: Testosterone Cypionate
Other: Questionnaire Administration

First Posted Date: 2021-02-01

Last Posted Date: 2024-12-27

Lead Sponsor: Emory University

Target Recruit Count: 100

Registration Number: NCT04731376

Locations: 🇺🇸
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy